<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>426-PRAVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PRAVASTATIN" rxcui="42463">
<ATC code="C10AA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
<ATC code="A02BD06" />
<ATC code="A02BD07" />
<ATC code="A02BD05" />
<ATC code="A02BD04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentration of the pravastatin by the clarithromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring during the treatment with the antibiotic</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>426-PRAVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PRAVASTATIN" rxcui="42463">
<ATC code="C10AA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="D10AF52" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring during the treatment with the antibiotic.</COMMENT>
</INTERACTION>
</INTERACTIONS>
